ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. North America is expected to lead with 46% market share, while Asia Pacific shows the highest growth rate at 16.69% CAGR.

Quantedge Capital added 212,600 shares of 10x Genomics in Q1 2026 for approximately $4.25 million, signaling investor confidence in the company. The stock has surged 116% over the past year, significantly outperforming the S&P 500's 26% gain. Despite being unprofitable, 10x Genomics showed improving fundamentals with 9% adjusted revenue growth, 70% gross margins, and the launch of Atera, a significant new spatial biology platform.

The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.

Ark Invest unveiled its 'big ideas' for 2026 through cryptic ARKmoji images, challenging users to interpret six investment themes: AI Agents, Genomics, Space Race (reusable rockets), Cryptocurrencies/Tokenization, Robotics, and The Great Acceleration. The firm highlighted portfolio holdings aligned with each theme, spanning multiple sectors from biotech to defense and space technology.

Global tumor transcriptomics market projected to grow from $6.02 billion in 2024 to $8.71 billion by 2030, driven by rising cancer prevalence and genomic sequencing advancements, with spatial transcriptomics emerging as a key technological trend.

Lancaster Investment Management acquired a new $7.27 million position in 10x Genomics during Q3 2025, purchasing 621,779 shares representing 3.1% of its assets under management.

The global Single-cell Analysis Market is projected to grow from USD 3.90 billion in 2024 to USD 12.29 billion by 2032, with a 13.61% CAGR, driven by increasing cancer research, precision medicine, and advanced genomics technologies.

The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.

The global single cell multiomics market is expected to grow from $3.78 billion in 2023 to $18.90 billion by 2033, at a CAGR of 19.58%. The growth is driven by increasing demand for advanced research solutions, rise in biomedical research and precision medicine, and technological advancements.